Findlay Park Partners LLP Reduces Stake in STERIS plc $STE

Findlay Park Partners LLP trimmed its position in shares of STERIS plc (NYSE:STE) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 747,152 shares of the medical equipment provider’s stock after selling 13,500 shares during the quarter. STERIS makes up 1.9% of Findlay Park Partners LLP’s portfolio, making the stock its 21st biggest holding. Findlay Park Partners LLP owned 0.76% of STERIS worth $184,875,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in shares of STERIS in the 2nd quarter worth about $289,132,000. Orbis Allan Gray Ltd raised its position in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after acquiring an additional 556,088 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of STERIS by 246.4% in the third quarter. Thrivent Financial for Lutherans now owns 553,834 shares of the medical equipment provider’s stock valued at $137,041,000 after purchasing an additional 393,970 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of STERIS by 32.2% in the second quarter. Invesco Ltd. now owns 1,220,699 shares of the medical equipment provider’s stock valued at $293,236,000 after purchasing an additional 297,076 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of STERIS by 305.9% in the third quarter. Assenagon Asset Management S.A. now owns 330,907 shares of the medical equipment provider’s stock valued at $81,880,000 after purchasing an additional 249,386 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Trading Down 0.9%

Shares of STE opened at $252.36 on Friday. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The company has a market capitalization of $24.75 billion, a PE ratio of 35.20 and a beta of 1.03. The stock has a fifty day moving average of $255.83 and a two-hundred day moving average of $251.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s dividend payout ratio is currently 35.15%.

Analyst Ratings Changes

A number of research firms recently issued reports on STE. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.